Inovio Pharmaceuticals Inc (INO)

[biovalidator]

Inovio affiliate VGX International is developing a gene therapy for obesity.
http://www.vgxi.com/bbs/bbs/board.php?bo_table=news&wr_id=341

"VGX Inter (KOSPI, 011000) today, "Industry-Academic Cooperation Foundation, Yonsei University, Seoul Paik Hospital, Inje University researchers in collaboration with the plasmid-based adiponectin (adiponectin) to develop a gene therapy of obesity and metabolic cooperation was signed a memorandum of understanding," he said . Accordingly, VGX Inter metabolism in obesity candidate gene therapy that holds the license to produce the electroporation device companies (brand name: select d) provided with, and the national authority in Obesity Research, Yonsei University, Professor of Food Science and Nutrition, Park, Tae - Seon The researchers evaluated the efficacy of animal testing is scheduled through. Clinical studies in the treatment of obesity in Korea, Seoul Paik Hospital, Inje University obesity expert gangjaeheon Center, as was the professor in charge. obesity treatment drugs on the market in 1999, the first time, many commercial products, but about 75,000 million to $ 2,019 in 2012 , approximately $ 2.6 billion expected to grow by an annual average being 20.7%. Our products include Xenical and Reductil interrupted, etc., but there are few side effects of therapeutic drug development are desperately needed a new situation. VGX Inter bakyounggeun said "existing concerns about the safety of obesity are high, but this joint research DNA drug side effects develop with less obesity, weight control, as well as to metabolic control has the advantage of being, "and" our plasmid-based technology, the domestic well-known researchers and joint research quickly to a safe and effective obesity treatment develop and improve the quality of life of individuals and is expected to contribute to public health, "he said.